로딩 중…
StockDiggingStockDigging

HYUNDAI PHARMACEUTICAL CO., LTD

004310· KOSPI
₩8,150-4.12%
2026-06-19

Price Chart

HYUNDAI PHARMACEUTICAL CO., LTD+134.20%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap260.80B KRW
Revenue195.16B KRW
Net Income811,296 KRW
Total Assets224.31B KRW
Net Assets134.81B KRW
Employees401
Value
P/B1.93x
P/S1.34x
EV/EBITDA98.01x
FCF Yield-1.81%
Profitability
ROE0.00%
ROA0.00%
Op. Margin1.53%
Revenue Growth7.82%
Financial Health
Debt Ratio166.38%
Total Debt49.80B KRW
FCF-4.73B KRW
Cash18.67B KRW
Current Ratio1.28x
Net Debt/EBITDA10.45x
Dividend
Div. Yield0.35%
Div. Growth0.00%
Performance
1Y Return134.20%
1M Return12.41%
From 52W High-48.93%
1Y MDD-61.58%
Trading
Volume14,841,315 shares
Foreign Own.6.80%
Per Share
EPS123 KRW
BPS4,878 KRW

Company Info

CEO 이상준
Employees 401
Founded 1965
HQ 충청남도 천안시, KR

Hyundai Pharmaceutical, established in 1965 and listed on the stock market in 1978, is a pharmaceutical and beverage manufacturing and sales company. It produces and supplies both specialized prescription drugs (such as hypertension treatment Tenormin) and over-the-counter drugs (like alopecia treatment Minoxidil Solution and mosquito bite relief Burmuli) to hospitals, clinics, and pharmacies nationwide. The company is currently conducting Phase 2b clinical trials for HDNO-1605, an innovative new drug for diabetes, and actively seeking improved new drugs to enhance medication adherence in the cardiovascular sector. Hyundai Pharmaceutical is headquartered in Cheonan-si, Chungcheongnam-do.